Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,EVAX,27703000.0,19198700,3893000,,-4500000,,-4093000,1282000,0,-5175000,-5175000,,,,,,-407000,0,5175000,0,675000,,-4093000,-4093000,96000.0,56254000.0,7121000.0,27799000.0,2553000.0,34920000.0,3132000.0,19000.0,-31078000.0,52000.0,-509000.0,737000.0,26955000.0,6016000.0,179000.0,-509000.0,1600000.0,32487000.0,1612000.0,3408000.0,15000.0,0.0,-327000.0,-43000.0,25252000.0,1038000.0,27900000.0,21121000.0,231000.0,-4035000.0,-2605000.0,-980000.0,-282000.0,,,,26471000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NCM,USD,8.2924,1630510933,1.7624002,7.33,9.6,7.26,2567232,6.53,7.85,7.93,10,11,finmb_319014926,NasdaqCM,Evaxion Biotech A/S,USD,76309,31966,3.1374002,0.608613,5.155 - 10.34,-2.0475998,-0.19802706,5.155,10.34,1628771400,1628771400,1628771400,REGULAR,us_market,Evaxion Biotech A/S,0,False,False,2,26.989283,7.26 - 9.6,-1.29,-6.4282174,5.7461667,2.5462337,0.44311866,6.6151958,1.6772046,0.25353816,159203312,15,America/New_York,EDT,-14400000,,,,10.34,5.16,5.75,6.62,76.31k,31.97k,19.2M,,9.35M,0.00%,4.60%,5.07k,0.04,,0.03%,3.56k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-18.34M,-16.01M,,,26.95M,1.4,1.11M,3.99,5.40,,-13.52M,,Value,2970,Healthcare,35,"Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.",Hoersholm,45 53 53 18 50,1609372800,Denmark,http://www.evaxion-biotech.com,86400,Dr. Neergaards Vej 5f DK,Biotechnology
t-1,EVAX,6938000.0,19198700,2854000,,-4766000,,-4264000,1791000,0,-4645000,-4645000,,-20000.0,,,,-502000,0,4645000,0,-121000,,-4264000,-4264000,100000.0,31443000.0,4927000.0,7038000.0,180000.0,11965000.0,2648000.0,1729000.0,-27279000.0,,226000.0,694000.0,5834000.0,4927000.0,262000.0,226000.0,221000.0,10950000.0,1794000.0,2646000.0,15000.0,1798000.0,-281000.0,-20000.0,2374000.0,814000.0,2394000.0,-2042000.0,258000.0,-4393000.0,-2605000.0,-269000.0,-72000.0,29000.0,-209000.0,-2501000.0,6023000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NCM,USD,8.2924,1630510933,1.7624002,7.33,9.6,7.26,2567232,6.53,7.85,7.93,10,11,finmb_319014926,NasdaqCM,Evaxion Biotech A/S,USD,76309,31966,3.1374002,0.608613,5.155 - 10.34,-2.0475998,-0.19802706,5.155,10.34,1628771400,1628771400,1628771400,REGULAR,us_market,Evaxion Biotech A/S,0,False,False,2,26.989283,7.26 - 9.6,-1.29,-6.4282174,5.7461667,2.5462337,0.44311866,6.6151958,1.6772046,0.25353816,159203312,15,America/New_York,EDT,-14400000,,,,10.34,5.16,5.75,6.62,76.31k,31.97k,19.2M,,9.35M,0.00%,4.60%,5.07k,0.04,,0.03%,3.56k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-18.34M,-16.01M,,,26.95M,1.4,1.11M,3.99,5.40,,-13.52M,,Value,2970,Healthcare,35,"Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.",Hoersholm,45 53 53 18 50,1609372800,Denmark,http://www.evaxion-biotech.com,86400,Dr. Neergaards Vej 5f DK,Biotechnology
t-2,EVAX,9362000.0,19198700,2510000,,-3279000,,-3099000,781000,0,-3291000,-3291000,,-20000.0,,,,-180000,0,3291000,0,12000,,-3099000,-3099000,,,,9362000.0,,,,,,,,,,,,,,,,,-17000.0,0.0,-81000.0,-18000.0,-18000.0,-358000.0,2394000.0,-3214000.0,-165000.0,-2950000.0,-2605000.0,507000.0,-64000.0,29000.0,-209000.0,-2501000.0,,en-US,US,EQUITY,True,Nasdaq Real Time Price,NCM,USD,8.2924,1630510933,1.7624002,7.33,9.6,7.26,2567232,6.53,7.85,7.93,10,11,finmb_319014926,NasdaqCM,Evaxion Biotech A/S,USD,76309,31966,3.1374002,0.608613,5.155 - 10.34,-2.0475998,-0.19802706,5.155,10.34,1628771400,1628771400,1628771400,REGULAR,us_market,Evaxion Biotech A/S,0,False,False,2,26.989283,7.26 - 9.6,-1.29,-6.4282174,5.7461667,2.5462337,0.44311866,6.6151958,1.6772046,0.25353816,159203312,15,America/New_York,EDT,-14400000,,,,10.34,5.16,5.75,6.62,76.31k,31.97k,19.2M,,9.35M,0.00%,4.60%,5.07k,0.04,,0.03%,3.56k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-18.34M,-16.01M,,,26.95M,1.4,1.11M,3.99,5.40,,-13.52M,,Value,2970,Healthcare,35,"Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.",Hoersholm,45 53 53 18 50,1609372800,Denmark,http://www.evaxion-biotech.com,86400,Dr. Neergaards Vej 5f DK,Biotechnology
t-3,EVAX,9362000.0,19198700,2946000,,-3778000,,-3519000,777000,0,-3723000,-3723000,,-39000.0,,,,-259000,0,3723000,0,-55000,,-3519000,-3519000,,22862000.0,1722000.0,9362000.0,177000.0,11084000.0,2481000.0,,-15812000.0,,-169000.0,25000.0,9559000.0,1722000.0,,-169000.0,101000.0,10958000.0,931000.0,646000.0,-17000.0,507000.0,-54000.0,-18000.0,244000.0,-156000.0,262000.0,-1912000.0,105000.0,-2207000.0,-2605000.0,1268000.0,-47000.0,30000.0,-7000.0,-337000.0,9236000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,NCM,USD,8.2924,1630510933,1.7624002,7.33,9.6,7.26,2567232,6.53,7.85,7.93,10,11,finmb_319014926,NasdaqCM,Evaxion Biotech A/S,USD,76309,31966,3.1374002,0.608613,5.155 - 10.34,-2.0475998,-0.19802706,5.155,10.34,1628771400,1628771400,1628771400,REGULAR,us_market,Evaxion Biotech A/S,0,False,False,2,26.989283,7.26 - 9.6,-1.29,-6.4282174,5.7461667,2.5462337,0.44311866,6.6151958,1.6772046,0.25353816,159203312,15,America/New_York,EDT,-14400000,,,,10.34,5.16,5.75,6.62,76.31k,31.97k,19.2M,,9.35M,0.00%,4.60%,5.07k,0.04,,0.03%,3.56k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-18.34M,-16.01M,,,26.95M,1.4,1.11M,3.99,5.40,,-13.52M,,Value,2970,Healthcare,35,"Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.",Hoersholm,45 53 53 18 50,1609372800,Denmark,http://www.evaxion-biotech.com,86400,Dr. Neergaards Vej 5f DK,Biotechnology
